|
|
||||||||
Department of International Health, Johns Hopkins University School of Public Hygiene, Baltimore, Md., USA.
This paper discusses some of the ethical challenges raised by advanced clinical trials designed to assess the safety and efficacy of vaginal microbicides in protecting women from HIV infection. The ethical principles that guide clinical research involving human subjects require that all participants in such trials be provided available measures known to reduce the risk of HIV infection. However, this will reduce the ability of the study to assess the protective effect of the test microbicide. In addition, providing extensive services to trial participants may be construed as an undue inducement if the study is being conducted among vulnerable groups such as sex workers or women from disadvantaged communities. Suggestions are provided to resolve this dilemma in the planning and implementation of HIV prevention services for trial participants.
This article has been cited by other articles:
![]() |
A M Minnis and N S Padian Effectiveness of female controlled barrier methods in preventing sexually transmitted infections and HIV: current evidence and future research directions Sex Transm Inf, June 1, 2005; 81(3): 193 - 200. [Abstract] [Full Text] [PDF] |
||||
![]() |
K Shapiro and S R Benatar HIV prevention research and global inequality: steps towards improved standards of care J. Med. Ethics, January 1, 2005; 31(1): 39 - 47. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. A. Brennan Proposed Revisions to the Declaration of Helsinki -- Will They Weaken the Ethical Principles Underlying Human Research? N. Engl. J. Med., August 12, 1999; 341(7): 527 - 531. [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |